Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19423616
Srisakuldee W, et al. (2009) Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res 83, 672-81 19423616
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S262-p - GJA1 (rat)
Modsite: sPskDCGsPkyAyFN SwissProt Entrez-Gene
Orthologous residues
GJA1 (human): S262‑p, GJA1 (mouse): S262‑p, GJA1 (rat): S262‑p, GJA1 (rabbit): S262‑p, GJA1 (pig): S262‑p, GJA1 (hamster): S262‑p, GJA1 (cow): S263‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'heart, embryo'
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase
FGF2 increase

S368-p - GJA1 (rat)
Modsite: QRPssRAssRAssRP SwissProt Entrez-Gene
Orthologous residues
GJA1 (human): S368‑p, GJA1 (mouse): S368‑p, GJA1 (rat): S368‑p, GJA1 (rabbit): S368‑p, GJA1 (pig): S368‑p, GJA1 (hamster): S368‑p, GJA1 (cow): S369‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'heart, embryo'
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase
FGF2 increase